Editas Medicine, Inc. 8-K

What Happened

• On March 9, 2026, Editas Medicine, Inc. (NASDAQ: EDIT) announced its financial results for the fiscal quarter and year ended December 31, 2025 via a press release.
• The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The Form 8‑K was signed by Amy Parison, Chief Financial Officer.
• The company described additional business highlights in the press release; investors should review Exhibit 99.1 for the full earnings, revenue and operational details.

Key Details

• Filing date: March 9, 2026 (Form 8‑K).
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Exhibit: 99.1 — press release announcing results and business highlights (furnished, not filed).
• Authorized signatory: Amy Parison, Chief Financial Officer.

Why It Matters

• This filing signals that Editas has released its latest quarterly and annual earnings and operational updates — information material to investors assessing recent revenue, cash position, and program progress.
• Because the press release is furnished as an exhibit, investors should read Exhibit 99.1 and watch for any subsequent filings (e.g., Form 10‑K, earnings call) for complete financial statements, metrics, and management commentary.
• Key takeaways for retail investors will come from the press release figures and any follow-up guidance or disclosures in later SEC filings.